+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the effectiveness of dotinurad compared with allopurinol in lowering serum uric acid levels in adults with gout-related hyperuricemia. This Phase 3 randomized study focuses on measuring the proportion of participants achieving target serum uric acid levels at Week 24. It aims to provide insights into treatment options for people living with gout. Participants will be randomly assigned to one of three groups one group will continue allopurinol at their current stable dose once daily through Week 64, while the other two groups will receive dotinurad with dose escalation over time. Dotinurad dosing starts at 1 mg daily for the first 4 weeks, increasing to 2 mg daily through Week 64 for one group, and for the other group, it increases from 1 mg daily for 4 weeks to 2 mg daily for 8 weeks, then 4 mg daily through Week 64. Throughout the study, participants will undergo regular assessments including serum uric acid level measurements and gout flare monitoring from baseline through Week 68. Safety will also be tracked by recording adverse events. The main outcome is the percentage of participants with serum uric acid below 6.0 mgdL at Week 24. The total study duration per participant extends up to approximately 68 weeks, with ongoing evaluations to assess gout flare frequency and other relevant outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
119 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.

Age: 18Years - 75YearsAll GendersPhase 3
272 locations
A

Actively Recruiting

Researchers are evaluating bimekizumab administered intravenously compared to subcutaneous injection in adults with active psoriatic arthritis or active axial spondyloarthritis. The study aims to show that the intravenous method is not less effective than the subcutaneous method by assessing how the drug moves in the body over time. This is a Phase 1, open-label, randomized, parallel-group study focused on treatment. Participants will receive one of three dosing regimens of bimekizumab during a pharmacokinetics lead-in phase and continue with the same assigned regimen during the treatment period. The dosing regimens include intravenous and subcutaneous administration of bimekizumab at specified times. Subjects are randomized into one of two experimental arms reflecting different intravenous regimens or a third arm receiving the subcutaneous regimen. During the study, participants will be monitored for steady-state trough concentration of the drug at week 16. Safety is assessed by tracking treatment-emergent adverse events, serious adverse events, and any events leading to withdrawal from the study through week 29. The study duration extends to the end of safety follow-up, with regular assessments to evaluate drug levels and participant health under medical supervision.

Age: 18Years +All GendersPhase 1
63 locations